Prognostic Influence of Increased C-Reactive Protein and Fibrinogen Levels in Ischemic Stroke

Background and Purpose— The prognostic influences of fibrinogen and C-reactive protein (CRP) levels and their relations in ischemic stroke have not been well described. The aim of this study was to investigate and compare the 1-year prognostic influences of fibrinogen and CRP levels on outcome in ischemic stroke. Methods— Fibrinogen and CRP were determined within 24 hours after stroke and related to 1-year outcome in 128 patients with first-ever ischemic stroke. The Kaplan-Meier technique was applied in survival analysis. Multiple logistic regression analysis was used to evaluate the associations between risk factors and outcome. Results— The probabilities of death or new vascular event were 21.1%, 27.9%, and 51.7% (P =0.0172, &khgr;2 for trend), respectively, in patients stratified by tertiles of fibrinogen (<3.78, 3.78 to 6.17, and >6.17 g/L). The probabilities of a primary end point were 12.1%, 29.7%, and 54.8% (P =0.0004), respectively, after stratification of patient data by tertiles of CRP level (<5, 5 to 33, and >33 mg/L). In multiple logistic regression analysis, higher CRP levels (odds ratio, 2.39; 95% CI, 1.28 to 4.49;P =0.0066) and stroke severity on the Canadian Neurological Stroke Scale (odds ratio, 2.37; 95% CI, 1.01 to 5.58;P =0.0472) were independently associated with death or new vascular event. Conclusions— Increased levels of CRP are associated with a worse outcome in patients with ischemic stroke. The increased risk associated with elevated CRP levels is independent of the prognostic influence of fibrinogen.

[1]  M. Di Napoli,et al.  C-reactive protein and outcome after first-ever ischemic stroke. , 2000, Stroke.

[2]  V. Bocola,et al.  C-Reactive Protein After First-Ever Ischemic Stroke , 1999 .

[3]  M. Moskowitz,et al.  Pathobiology of ischaemic stroke: an integrated view , 1999, Trends in Neurosciences.

[4]  K. Lees,et al.  C-reactive protein and outcome after ischemic stroke. , 1999, Stroke.

[5]  D. Briley,et al.  Persistent inflammatory response in stroke survivors , 1998, Neurology.

[6]  R. Tracy Inflammation in cardiovascular disease: cart, horse, or both? , 1998, Circulation.

[7]  C. Marini,et al.  High stroke incidence in the prospective community-based L'Aquila registry (1994-1998). First year's results. , 1997, Stroke.

[8]  A. Grau Infection, inflammation, and cerebrovascular ischemia , 1997, Neurology.

[9]  M. Dennis A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee , 1996 .

[10]  David Schultz,et al.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996, The Lancet.

[11]  W. Feinberg,et al.  Hemostatic markers in acute ischemic stroke. Association with stroke type, severity, and outcome. , 1996, Stroke.

[12]  MichalBenderly,et al.  Fibrinogen Is a Predictor of Mortality in Coronary Heart Disease Patients , 1996 .

[13]  I. Sartori Hemostatic Factors and the Risk of Myocardial Infarction or Sudden Death in Patients with Angina Pectoris , 1996 .

[14]  D. Clement A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996 .

[15]  P. Savage,et al.  Fibrinogen and factor VIII, but not factor VII, are associated with measures of subclinical cardiovascular disease in the elderly. Results from The Cardiovascular Health Study. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[16]  A. Simon,et al.  Fibrinogen and silent atherosclerosis in subjects with cardiovascular risk factors. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[17]  B. Coull,et al.  Interleukin‐6 and interleukin‐1 receptor antagonist in acute stroke , 1995, Annals of neurology.

[18]  F. Galetta,et al.  [Fibrinogen as a cardiovascular risk factor]. , 1995, Minerva cardioangiologica.

[19]  G. Assmann,et al.  Association of Variables of Coagulation, Fibrinolysis and Acute-phase with Atherosclerosis in Coronary and Peripheral Arteries and those Arteries Supplying the Brain , 1995, Thrombosis and Haemostasis.

[20]  G. Assmann,et al.  Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[21]  G. Vercellotti,et al.  C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor , 1993 .

[22]  E. Ernst,et al.  Fibrinogen as a Cardiovascular Risk Factor , 1993, Annals of Internal Medicine.

[23]  Harry,et al.  C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. , 1993, Blood.

[24]  A. Banerjee,et al.  A Six Year Prospective Study of Fibrinogen and Other Risk Factors Associated with Mortality in Stable Claudicants , 1992, Thrombosis and Haemostasis.

[25]  E. Ernst,et al.  Fibrinogen and Viscosity as Risk Factors for Subsequent Cardiovascular Events in Stroke Survivors , 1992, Annals of Internal Medicine.

[26]  M. Burr,et al.  Haematological prognostic indices after myocardial infarction: evidence from the diet and reinfarction trial (DART). , 1992, European heart journal.

[27]  M. Burr,et al.  Influence of platelet size on outcome after myocardial infarction , 1991, The Lancet.

[28]  J. Bamford,et al.  Classification and natural history of clinically identifiable subtypes of cerebral infarction , 1991, The Lancet.

[29]  P C Elwood,et al.  Fibrinogen, Viscosity, and White Blood Cell Count Are Major Risk Factors for Ischemic Heart Disease: The Caerphilly and Speedwell Collaborative Heart Disease Studies , 1991, Circulation.

[30]  Daniel B Hier,et al.  The Stroke Data Bank: design, methods, and baseline characteristics. , 1988, Stroke.

[31]  V. Nguyen Fibrinogen and risk of cardiovascular disease: Kannel WB, Wolf PA, Castelli WP, et al JAMA 258: 1183–1186 Sep 1987 , 1988 .

[32]  R. D'Agostino,et al.  Fibrinogen and risk of cardiovascular disease. The Framingham Study. , 1987, JAMA.

[33]  R Côté,et al.  The Canadian Neurological Scale: a preliminary study in acute stroke. , 1986, Stroke.

[34]  M. C. Stone,et al.  Plasma fibrinogen--a major coronary risk factor. , 1985, The Journal of the Royal College of General Practitioners.

[35]  J. Volanakis COMPLEMENT ACTIVATION BY C‐REACTIVE PROTEIN COMPLEXES * , 1982, Annals of the New York Academy of Sciences.

[36]  J. Kostis,et al.  Association of recurrent myocardial infarction with hemostatic factors: a prospective study. , 1982, Chest.

[37]  S. Thompson,et al.  HÆMOSTATIC FUNCTION AND CARDIOVASCULAR DEATH: EARLY RESULTS OF A PROSPECTIVE STUDY , 1980, The Lancet.

[38]  S. Thompson,et al.  Haemostatic function and cardiovascular death: early results of a prospective study. , 1980, Lancet.

[39]  Classification and Diagnosis of Diabetes Mellitus and Other Categories of Glucose Intolerance , 1979, Diabetes.

[40]  F. Mahoney,et al.  FUNCTIONAL EVALUATION: THE BARTHEL INDEX. , 2018, Maryland state medical journal.

[41]  Mahoney Fi,et al.  FUNCTIONAL EVALUATION: THE BARTHEL INDEX. , 1965 .